About guselkumab
Interleukin-23 inhibitor
Used for
- Plaque psoriasis
- Psoriatic arthritis
- Ulcerative colitis
- Crohn’s disease
Usual adult dose
Psoriasis or psoriatic arthritis: 100 mg under the skin at weeks 0 and 4, then every 8 weeks. Bowel disease: intravenous induction, followed by under-the-skin maintenance dosing.
Common side effects
- Upper respiratory infections
- Headache
- Injection-site reactions
- Joint pain
Important warnings
- Serious infections can occur; treatment may be delayed during infection.
- Screen for tuberculosis before treatment.
- Avoid live vaccines during treatment.
- Infusion reactions and allergic reactions are possible.
Pregnancy
Human pregnancy data are limited; use requires weighing potential benefits and risks.
Breastfeeding
It is unknown whether guselkumab passes into breast milk; discuss benefits and potential risks.
Interactions
- Live vaccines may be unsafe during treatment.
- Other biologic immune-suppressing medicines may increase infection risk.
AI-generated from general medical knowledge, not from this product's official leaflet. It may be incomplete or out of date. Not medical advice — ask a pharmacist or doctor before making any decision.